AZN.ST - AstraZeneca PLC

Stockholm - Stockholm Real-time price. Currency in SEK
549.40
-1.20 (-0.22%)
At close: 5:29PM CET
Stock chart is not supported by your current browser
Previous close550.60
Open547.70
Bid549.40 x 0
Ask549.60 x 0
Day's range546.80 - 551.80
52-week range461.30 - 622.00
Volume388,169
Avg. volume456,521
Market cap652.22B
BetaN/A
PE ratio (TTM)231.81
EPS (TTM)2.37
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est83.53
  • U.S. health officials reverse stance on AstraZeneca's flu vaccine
    Reutersyesterday

    U.S. health officials reverse stance on AstraZeneca's flu vaccine

    The latest recommendation follows results from a U.S. study in young children that showed vaccines containing a 2017-2018 strain of H1N1 flu virus performed better than the 2015-2016 strain that had shown decreased effectiveness, AstraZeneca said.

  • Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
    Zacksyesterday

    Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M

    Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.

  • 3 High-Yield Stocks Still Worth Buying
    Motley Fool3 days ago

    3 High-Yield Stocks Still Worth Buying

    Many dividend stocks are overpriced, but these investors have identified three you should consider buying now.

  • AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
    Zacks3 days ago

    AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion

    Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.

  • Reuters4 days ago

    AstraZeneca's immunotherapy drug wins key lung cancer approval

    AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. The U.S. Food and Drug Administration (FDA) said late on Friday it had granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body. Imfinzi is the first immunotherapy to be approved in this setting and the company's shares rose 1 percent in early trade on Monday.

  • Reuters - UK Focus4 days ago

    AstraZeneca's immunotherapy drug wins key lung cancer approval

    AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. The U.S. Food and Drug Administration (FDA) said late on Friday it had granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body. Imfinzi is the first immunotherapy to be approved in this setting and the company's shares rose 1 percent in early trade on Monday.

  • Reuters6 days ago

    U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

    Lung cancer is the leading cause of cancer death in the United States, with an estimated 222,500 new diagnoses and 155,870 deaths in 2017, according to the National Cancer Institute. In 2017, the drug was approved to treat a type of bladder cancer in patients whose disease progressed despite chemotherapy.

  • MarketWatch16 days ago

    Bristol-Myers touts lung cancer breakthrough, but critics cry foul

    The drugmaker says its findings advanced the scientific understanding of how to treat lung cancer, but critics say a major overhaul of the clinical trial design sullied the results.

  • Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint
    Zacks17 days ago

    Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint

    Losses on Wall Street and falling bond yields weighed on global markets this week.

  • AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
    Investor's Business Daily20 days ago

    AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro

    AstraZeneca's Lynparza is now king of the U.S. PARP inhibitor realm — beating out Tesaro — an analyst said Friday.

  • MarketWatch20 days ago

    FTSE 100 suffers worst week since April as bond yields spike

    U.K.’s benchmark stock index dropped for a fourth straight day on Friday, extending its weekly loss, after bond yields spiked following a better-than-expected reading on the U.S. labor market.

  • Reuters20 days ago

    Results, risk aversion drag FTSE 100 to worst week in nine months

    By Kit Rees LONDON (Reuters) - Britain's top share index sealed its worst week in nine months on Friday after results from BT were met with disappointment and commodities stocks tumbled amid a global equity ...

  • AstraZeneca's core numbers hide pharma firm's progress
    Sky News20 days ago

    AstraZeneca's core numbers hide pharma firm's progress

    Not for the first time results today from AstraZeneca (Swiss: AZN.SW - news) (AZ (Stuttgart: A1131G - news) ), the UK's second-largest drug maker, are something of a curate's egg. Pascal Soriot, chief executive, had previously promised that 2017 would be the year that the Cambridge-based company's sales would start to grow again.

  • Reuters20 days ago

    AstraZeneca flags return to drug growth in 2018, China shines

    AstraZeneca (AZN.L) expects a return to drug sales growth in 2018 as new medicines win market share and the group puts patent losses behind it, although the need to invest in launches will weigh on profit this year. AstraZeneca has suffered the industry's biggest patent cliff since 2012, wiping out more than half of its sales, but Chief Executive Pascal Soriot said it was turning a corner and spending as a proportion of sales would reduce by 2019-20. After a 5 percent fall in 2017, the group expects drug sales this year to grow at a low single-figure percentage rate, driven by new treatments for cancer, in particular, and buoyed by 20 percent-plus sales growth in China.

  • Reuters - UK Focus20 days ago

    AstraZeneca flags return to drug growth in 2018, China shines

    AstraZeneca (NYSE: AZN - news) expects a return to drug sales growth in 2018 as new medicines win market share and the group puts patent losses behind it, although the need to invest in launches will weigh on profit this year. AstraZeneca has suffered the industry's biggest patent cliff since 2012, wiping out more than half of its sales, but Chief (Taiwan OTC: 3345.TWO - news) Executive Pascal Soriot said it was turning a corner and spending as a proportion of sales would reduce by 2019-20. After a 5 percent fall in 2017, the group expects drug sales this year to grow at a low single-figure percentage rate, driven by new treatments for cancer, in particular, and buoyed by 20 percent-plus sales growth in China.

  • AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018
    Zacks20 days ago

    AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018

    AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.

  • Reuters20 days ago

    AstraZeneca links with Alibaba and Tencent in China push

    AstraZeneca (AZN.L) has clinched two new deals with Chinese tech giants Alibaba (BABA.N) and Tencent as the British drugmaker steps up its drive to expand business in China. China is now the world's second-largest drugs market behind the United States and is a particular bright spot for AstraZeneca, accounting for 15 percent of its drug sales -- a far higher proportion than at other big pharmaceutical companies. AstraZeneca's sales in China grew 30 percent in the last quarter of 2017 and Chief Executive Pascal Soriot expects them to continue to increase at a "low-20s" percentage rate.

  • Reuters - UK Focus20 days ago

    AstraZeneca links with Alibaba and Tencent in China push

    AstraZeneca has clinched two new deals with Chinese tech giants Alibaba and Tencent as the British drugmaker steps up its drive to expand business in China. China is now the world's second-largest drugs ...

  • Associated Press20 days ago

    Astrazeneca beats 4Q profit forecasts

    The Cambridge, Britain-based company said it had net income of $1.03 per share. Earnings, adjusted for non-recurring costs, were $1.30 per share. The results exceeded Wall Street expectations. The average ...

  • Reuters - UK Focus20 days ago

    FTSE 100 heads for worst week in six months as results drag

    Britain's top share index retreated on Friday after results from BT and AstraZeneca were met with disappointment, rounding off a lacklustre week for British blue chips. The blue chip FTSE 100 index was ...

  • Associated Press21 days ago

    AstraZeneca reports boost in cancer drug sales

    LONDON (AP) — Anglo-Swedish drugmaker AstraZeneca is reporting its first quarterly sales in years on the back of new cancer treatments.

  • Reuters21 days ago

    AstraZeneca is sued by Array BioPharma over cancer drug royalties

    Array BioPharma Inc (ARRY.O) on Thursday sued AstraZeneca AB (AZN.L), accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion (5.96 billion pounds) collaboration with Merck & Co (MRK.N). In a complaint filed in the New York State Supreme Court in Manhattan, Array is seeking at least $192 million from AstraZeneca for the alleged breach of a 2003 licensing agreement related to the drug, known as selumetinib. AstraZeneca did not immediately respond to a request for comment.

  • Reuters - UK Focus21 days ago

    AstraZeneca is sued by Array BioPharma over cancer drug royalties

    Array BioPharma Inc (Frankfurt: 580564 - news) on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co (Swiss: MRK-USD.SW - news) . In a complaint filed in the New York State Supreme Court in Manhattan, Array is seeking at least $192 million from AstraZeneca (NYSE: AZN - news) for the alleged breach of a 2003 licensing agreement related to the drug, known as selumetinib. AstraZeneca did not immediately respond to a request for comment.

  • AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III
    Zacks24 days ago

    AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III

    AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.

  • MarketWatch27 days ago

    U.K. stocks rebound from 1-month low as AstraZeneca rises after trial results

    U.K. stock rebounded from a one-month low on Friday, shaking off a continued rally in the pound as drugmakers advanced after industry heavyweight AstraZeneca released positive trial results.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes